Competitor Analysis: NY-ESO-1-Targeted Immunotherapy
Competitor Analysis: NY-ESO-1-Targeted Immunotherapy
This Competitive Intelligence report analyzes the competitive field of NY-ESO-1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
The New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a human tumor antigen of the cancer/testis family (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
Cancer testis antigens are a unique class of tumor-associated antigens, because they are normally expressed in the adult male germ line, but not in other normal tissues, and are overexpressed in various malignancies. NY-ESO-1 being the most immunogenic among the cancer testis antigen family members. NY-ESO-1 spontaneously elicits humoral and cellular responses in many patients with cancer. Therefore, among tumor-associated antigens, it is one of the most promising antigens for immunotherapy, and different vaccines using NY-ESO-1 peptides, full-length NY-ESO-1 protein, or NY-ESO-1 DNA are being evaluated in clinical trials.
Transfer of T-cell receptors (TCRs) specific for tumor-associated antigens is another promising approach for cancer immunotherapy. NY-ESO-1 is expressed in 10 to 50% of metastatic melanomas, lung, breast, prostate, thyroid and ovarian cancers as well as between 70 and 80% of synovial cell sarcomas. Interim results from clinical studies of NY-ESO-1 specific TCR engineered T-cells suggest generally good tolerance with initial efficacy.
The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes and recombinant antibodies and proteins targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1). In addition, the report lists company- and institution-specific R&D pipelines of NY-ESO-1-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report analyzes the competitive field of NY-ESO-1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
The New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a human tumor antigen of the cancer/testis family (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
Cancer testis antigens are a unique class of tumor-associated antigens, because they are normally expressed in the adult male germ line, but not in other normal tissues, and are overexpressed in various malignancies. NY-ESO-1 being the most immunogenic among the cancer testis antigen family members. NY-ESO-1 spontaneously elicits humoral and cellular responses in many patients with cancer. Therefore, among tumor-associated antigens, it is one of the most promising antigens for immunotherapy, and different vaccines using NY-ESO-1 peptides, full-length NY-ESO-1 protein, or NY-ESO-1 DNA are being evaluated in clinical trials.
Transfer of T-cell receptors (TCRs) specific for tumor-associated antigens is another promising approach for cancer immunotherapy. NY-ESO-1 is expressed in 10 to 50% of metastatic melanomas, lung, breast, prostate, thyroid and ovarian cancers as well as between 70 and 80% of synovial cell sarcomas. Interim results from clinical studies of NY-ESO-1 specific TCR engineered T-cells suggest generally good tolerance with initial efficacy.
The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes and recombinant antibodies and proteins targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1). In addition, the report lists company- and institution-specific R&D pipelines of NY-ESO-1-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) NY-ESO-1-TARGETED IMMUNOTHERAPY
NY-ESO-1 Selective Cancer Vaccines
NY-ESO-1 Specific, Multi-Target Cancer Vaccines
NY-ESO-1 Selective Adoptive Cell Therapy
NY-ESO-1 Specific, Multi-Target Adoptive Cell Therapy
NY-ESO-1 Selective Recombinant Antibodies & Proteins
2) CORPORATE & INSTITUTIONAL NY-ESO-1 IMMUNOTHERAPY R&D PIPELINES
NY-ESO-1 Selective Cancer Vaccines
NY-ESO-1 Specific, Multi-Target Cancer Vaccines
NY-ESO-1 Selective Adoptive Cell Therapy
NY-ESO-1 Specific, Multi-Target Adoptive Cell Therapy
NY-ESO-1 Selective Recombinant Antibodies & Proteins
2) CORPORATE & INSTITUTIONAL NY-ESO-1 IMMUNOTHERAPY R&D PIPELINES
